Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference January 2026
8 slides from Immuron's conference presentation, Jan 23, 2026
Slide 1: Emerging Growth Conference January 2026
EMERGING GROWTH CONFERENCE 23 JANUARY 2026 NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as ” anticipates,” “expects,” “intends,” “plans,” “believes,” ” seeks,” “estimates,” “guidance” and s imilar expressions are intended
Slide 3: Immuron: Australian integrated biopharmaceutical company focused on gut-mediated diseases
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases Research & Development 3 pipeline assets in 2 clinical programmes Global footprint Australia, US, Canada and expan
Slide 4: FY25 Financial Achievements
FY25 Financial Achievements Global Sales Revenue $7.3m Up 49% Australian Sales Revenue $5.3m Up 40% North American Sales Revenue $2.0m Up 76% Gross Profit Margin 65.4% EBITDA (ex - R&D) 1 $(3.1)m $2.1m improvement Cash + Term Deposit 2,3 $5.9m 4 1 ex - R&D: add back research & development, less R&D
Slide 5: Travelan continued strong sales growth
Travelan® continued strong sales growth Global + FY2025 AUD$7.3 million up 49% on prior year + FY2026 H1 AUD$4.2 million up 5% on FY2025 H1 Australia + FY2025 AUD$5.2 million up 40% on prior year + FY2026 H1 AUD$3.3 million up 13% on FY2025 H1 North America + FY2025 AUD$2.0 million up 76% on prior y
Slide 6: FY25 Clinical Achievements and Operational Highlights
FY25 Clinical Achievements and Operational Highlights FDA approval IMM - 529 IND Travelan® n= 851 trial completed Travelan® Ph 2 statistically significant results 1 New research collaboration IMM - 986 (VRE) New product launch in Australia Updated peak U.S. sales for IMM - 529 US$400 million 2 1. Im
Slide 7: FY26 Outlook
FY26 Outlook Continued YoY sales growth Progression towards EBITDA (ex - R&D) 1 breakeven IMM - 986 (VRE) Pre - clinical data 1H 2026 Travelan ® End of Phase 2 Meeting with FDA 1H 2026 IMM - 529 Initiation of Phase 2 1H 2026 1 ex - R&D: add back research & development, less R&D Tax Incentive and R&D
Slide 8: Contact Information
STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 IMMURON I NVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH